Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ausrichter pty ltd - iron as iron polymaltose - parenteral liquid/solution/suspension - iron as iron polymaltose mineral - iron active 200.0 mg/ml - nutrition & metabolism - pig - piglet | neonatal piglet | new born pig | sucker pig - iron deficiency | anaemia

Australia - English - Department of Health (Therapeutic Goods Administration)

sigma company limited - iron polymaltose, quantity: 318 mg (equivalent: iron, qty 100 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - indications as at 8 april 2002: for the treatment of iron deficiency anaemia in the following circumstances: * when oral therapy is contraindicated. * when enteric absorption of iron is defective. * when patient non-compliance or persistent gastrointestinal intolerance makes oral therapy impractical.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - iron (iii) hydroxide polymaltose complex -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - iron (iii) hydroxide polymaltose complex -

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - iron sucrose, quantity: 540 mg/ml (equivalent: iron, qty 20 mg/ml) - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections - venofer is indicated for the treatment of iron deficiency anaemia in patients undergoing chronic haemodialysis and who are receiving supplemental erythropoietin therapy.,the diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. serum ferritin, serum iron, transferrin saturation and hypochromic red cells).

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - iron polymaltose, quantity: 370 mg (equivalent: iron, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 6000; crospovidone; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide yellow; iron oxide red - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate. prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

Philippines - English - FDA (Food And Drug Administration)

aglobal care, inc.; distributor: aglobal care, inc. - iron (as iron polymaltose complex) , folic acid , ascorbic acid - syrup - 50mg (equi. to 172mg iron polymaltose complex)/ 2mg/ 100mg per 5ml

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 5 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual du

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 15 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual d

United States - English - NLM (National Library of Medicine)

preferredpharmaceuticals inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 10 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual d